The research around best radiation-based treatment options for patients with hepatocellular carcinoma are over 15 years old, but the standard of care for long-term management of the disease is still conventional chemoembolization, according to Emil I. Cohen, MD, assistant professor, Georgetown University Hospital.
The research around best radiation-based treatment options for patients with hepatocellular carcinoma (HCC) are over 15 years old, but the standard of care for long-term management of the disease is still conventional chemoembolization, according to Emil I. Cohen, MD, assistant professor, Georgetown University Hospital.
Since the original data were released demonstrating a benefit in progression-free survival with chemoembolization, other studies have excluded patients who are transplant candidates. This is because physicians are more careful with these patients to ensure they continue to meet the criteria for transplantation, says Cohen. However, patients who are ineligible for a transplant have been enrolled in studies comparing radioembolization with conventional chemoembolization as a potential bridge to transplantation.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More